Abstract
Importance The opioid epidemic continues to grow, and while the adverse effects of opioids are well-known, their impact on short-term mortality in patients with dementia or mild cognitive impairment (MCI) remains understudied, despite the high vulnerability of this population.
Objective To evaluate the short-term mortality risk associated with initiating opioids in patients diagnosed with dementia or MCI
Design Retrospective observational cohort study
Setting Multisite healthcare system in Northern California
Participants Health records of 27,759 patients aged 50–100 with dementia or MCI, with encounters between January 1, 2015, and July 31, 2024. Exclusions included patients who died within 14 days of surgery, had fewer than three clinical encounters before and after diagnosis, or were first diagnosed with dementia/MCI at death.
Exposures Initial opioid use following dementia or MCI onset. Patients were categorized as new users (no opioid use in the prior year) or consistent users (prior opioid exposure).
Main Outcome and Measures Short-term mortality risk, defined as death within 14 days of first opioid exposure, with additional monitoring up to 60 and 180 days after opioid initiation. Hazard ratios were calculated using Cox proportional hazards regression, adjusting for demographics, comorbidities, and medication exposure. We used GPT.3.5-Turbo to identify possible causes of death from unstructured clinical documentation, supplemented by data from California public death records.
Results Among 14,107 patients prescribed opioids following the onset of dementia/MCI onset, 9444 were new users and 4663 were consistent users. The cohort was predominantly female (56.0%), with a median age of 81 years (IQR:73–87). New users exhibited a 1.95-fold (95% CI, 1.55–2.46; P < 0.0001) increased risk of mortality within 14 days of initial opioid exposure compared to consistent users. Respiratory illnesses were more prevalent among new users who died within 14 days after opioid exposure (62% vs. 48%, P<0.1), particularly pneumonia (38% vs. 19%, P<0.01).
Conclusion Opioid initiation in patients with dementia or MCI is linked to significantly higher short-term mortality, particularly in those with respiratory conditions. These findings highlight the need for cautious prescribing and close monitoring, given the increased mortality risk.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was supported by grant number R01HS024096 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Stanford University Institutional Review Board (Protocol 47644). Informed consent was waived under exemption 4: research on existing data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Figure 2 has been revised to reflect the most current version.
Data Availability
All clinical logic has been shared. Results have been aggregated and reported within this paper to the extent possible while maintaining privacy from personal health information as required by law.